{"id":1419,"date":"1999-05-01T12:05:00","date_gmt":"1999-05-01T10:05:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/1999\/leserbrief-bornaprin-und-sport"},"modified":"1999-05-01T12:05:00","modified_gmt":"1999-05-01T10:05:00","slug":"leserbrief-bornaprin-und-sport","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/1999\/leserbrief-bornaprin-und-sport","title":{"rendered":"Leserbrief: Bornaprin und Sport"},"content":{"rendered":"<p>Frage von Dr. R.B. aus Bremen: >> Kann es unter Gabe eines Anticholinergikums (Bornaprin 4 mg) zu merkenswerter Einschr\u00e4nkung der k\u00f6rperlichen Leistungsf\u00e4higkeit beim Ausdauertrainierten kommen? > Bornaprin (Sormodren) geh\u00f6rt zu den Anticholinergika und hat eine Antimuskarinwirkung. Anwendungsgebiete sind laut Roter Liste 1998 (7): Parkinson-Syndrom, insbesondere zur Beeinflussung des Rigors und des Tremors, medikament\u00f6s bedingte extrapyramidale [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Frage von Dr. R.B. aus Bremen: >> Kann es unter Gabe eines Anticholinergikums (Bornaprin 4 mg) zu merkenswerter Einschr\u00e4nkung der k\u00f6rperlichen Leistungsf\u00e4higkeit beim Ausdauertrainierten kommen? > Bornaprin (Sormodren) geh\u00f6rt zu den Anticholinergika und hat eine Antimuskarinwirkung. Anwendungsgebiete sind laut Roter Liste 1998 (7): Parkinson-Syndrom, insbesondere zur Beeinflussung des Rigors und des Tremors, medikament\u00f6s bedingte extrapyramidale [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[776,3407,1478],"class_list":["post-1419","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-anticholinergika","tag-bornaprin","tag-sport"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1419","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=1419"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1419\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=1419"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=1419"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=1419"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}